Global Medical Lead, Factor Replacement Therapies, PDT Global Medical AffairsTakeda Pharmaceuticals International AG, Zurich, SwitzerlandZurich, Zurich, Switzerland
PB1061 - A phase 3 trial of TAK-330 (4-factor prothrombin complex concentrate [4F-PCC]) vs standard-of-care 4F-PCCs for FXa inhibitor-induced anticoagulation reversal before urgent surgery/invasive procedure
Tuesday, June 25, 202413:45 – 14:45 ICT
PB1074 - Global prevalence of anticoagulant reversal for major bleeding and urgent surgery in patients with atrial fibrillation and venous thromboembolism: a systematic review of data from 38 countries
PB1063 - Safety assessment of Prothromplex®, a 4-factor prothrombin complex concentrate, focused on heparin-related adverse events
